Relationship Managers

Making a positive impact by offering valuable contacts, resources, and advice to strengthen relationships and foster mutual support..

Find out more

Project Marketing Consultants

Unlocking Diverse Investment Opportunities Across Sectors. We specialise in connecting investors with profitable prospects. Explore our portfolio and discover the potential of rewarding projects.

Find out more

What We Do

With an extensive business background spanning over three decades on a global scale, Bondal Shore is uniquely positioned to leverage the valuable relationships and knowledge cultivated across various arenas.

At Bondal Shore, our watchwords are help, trust, and care. As dedicated introducers, we forge connections across diverse business arenas, ensuring a seamless experience for our clients from start to finish.

At Bondal Shore, we bridge businesses and consumers, creating successful outcomes in every interaction. Our dedicated focus across diverse arenas ensures a seamless experience for our clients.

Our Services

Investment

Raise capital through diverse funding options, including equity, debt, and investment avenues.

Property project contracting and financing.

Specialized assistance in property project contracting and financing for successful developments.

Customer Targeted Relationship.

Cultivate strong customer-targeted relationships to maximize engagement and business growth.

Projects

 

Please complete contact us form for further information on all projects

 

Pierian Biosciences Ltd - Click to view more
Pierian Biosciences Inc in Nashville, Tennessee have developed two cancer treatment selective platforms.

ChemoIntel: In vitro bioassay for ranking chemotherapy in order of effectiveness for any individual patient. The ChemoIntel test is based on multiple parameters to eliminate outlier readings. The method has proved reliable as a personalised alternative to general standard of care prescribing.

ImmunoIntel: Diagnostic method for ranking immunotherapy treatments for cancer in order of effectiveness for any individual patient. Biopsy cells are

tested in reproduced micro environment conditions. The two assays, together, transform the process of choosing the right treatment for the right patient. It is believed insurers and health services will require this before paying for

treatment. It avoids treating patients with potentially harmful drugs and procedures that may not produce the desired response.

A unique wealth of valuable data has been built up over several years of development. This has considerable and enduring value in a field that is  chronically short of clinical data. Two new laboratories have now been opened in Liverpool allowing access to human tissue samples from across Europe. 

Pierian has now signed a Service Level Agreement with a major UK Cancer Hospital and moves forward with its Cancer Assay Algorithm Development Study prior to FDA trials. 

Targeted returns of x8

Exit horizon is 12 – 18 months.

Cancer Breakthrough Fund (Keyholder) - Click to view more

Cancer treatment outcomes have significantly improved over the past decade associated with the discovery and advancement of targeted therapies and immunotherapies.

Recent progress in the understanding of the biology of cancer now permits rational treatment selection significantly improving survival. Keyholder Funding Limited is providing selected investment opportunities in the field of Oncology.

The opportunities are de-risked, asset-based investment in some of the most exciting, disruptive and potentially profitable developments in the fight against cancer. The developments chosen to be in this investment programme are subjected to an extremely rigorous selection process. They are late stage, transitional assets to be taken to commercialisation.

Targeted returns of 8X initial investment.

Target term 18 months.

Our Team

David Derbyshire

David Derbyshire

Director

Email: davidd@bondalshore.com
Mobile: +44 7545 805612

David Hargrave

David Hargrave

Director

Email: davidh@bondalshore.com
Mobile: +44 7530 151334

Contact Us